# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Charles Duncan reiterates KalVista Pharma (NASDAQ:KALV) with a Overweight.
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.
Data was presented at the Bradykinin Symposium 2024 taking place in Berlin, Germany, on September 5-6. Sebetralstat is a novel,...
Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $32 price target.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), today announced that the U.S. Food and Drug Administration (FDA) has accepted its...
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.